Literature DB >> 11277

Extrapyramidal effects of neuroleptics.

A D Korczyn, G J Goldberg.   

Abstract

A study was conducted on 66 psychiatric inpatients who took major tranquilizers for periods of four to 16 years. The frequency of signs of Parkinsonism and the effects of orphenadrine on these were studied in a double-blind crossover method. Sixty-one per cent of the patients showed signs of Parkinsonism. Female patients and those with organic brain pathology more frequently exhibited Parkinsonism (although the difference was not statistically significant). No correlation was found between duration of treatment and extrapyramidal effects. Of the 40 patients who developed Parkinsonism, 25 responded favourably to orphenadrine, while six (15%) had more marked manifestations on orphenadrine than on placebo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 11277      PMCID: PMC492474          DOI: 10.1136/jnnp.39.9.866

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  A survey of drug-induced extrapyramidal reactions.

Authors:  F J AYD
Journal:  JAMA       Date:  1961-03-25       Impact factor: 56.272

2.  Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine.

Authors:  P L MCGEER; J E BOULDING; W C GIBSON; R G FOULKES
Journal:  JAMA       Date:  1961-09-09       Impact factor: 56.272

3.  Reversibility of drug-induced parkinsonism.

Authors:  R B CAHAN; D D PARRISH
Journal:  Am J Psychiatry       Date:  1960-05       Impact factor: 18.112

4.  Withdrawal of maintenance antiparkinson drug in the phenothiazine-induced extrapyramidal reaction.

Authors:  W MANDEL; W A OLIVER
Journal:  Am J Psychiatry       Date:  1961-10       Impact factor: 18.112

5.  Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.

Authors:  C J Klett; E Caffey
Journal:  Arch Gen Psychiatry       Date:  1972-04

Review 6.  Pathophysiology of drug-induced dyskinesias.

Authors:  A D Korczyn
Journal:  Neuropharmacology       Date:  1972-09       Impact factor: 5.250

7.  Orphenadrine ("Disipal") in the treatment of Parkinsonism: a two-year study of 150 patients.

Authors:  R R Strang
Journal:  Med J Aust       Date:  1965-09-11       Impact factor: 7.738

8.  Antiparkinson drugs and neuroleptics.

Authors:  C Morpurgo
Journal:  Prog Brain Res       Date:  1965       Impact factor: 2.453

9.  Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor.

Authors:  J Marshall; H Schnieden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1966-06       Impact factor: 10.154

  9 in total
  4 in total

1.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

2.  The pathophysiology of dystonia.

Authors:  A D Korczyn
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

3.  Anticholinergic antiparkinsonian therapy in outpatients treated with neuroleptic drugs: a prescription survey.

Authors:  S Spila-Alegiani; G Diana; F Menniti-Ippolito; R Raschetti
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Quantitative analysis of motor disturbances in schizophrenic patients.

Authors:  Albert Putzhammer; Helmfried E Klein
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.